Introducing Vernakalant into Clinical Practice

Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilita...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Angela JM, Mitchell, Andrew RJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Drugs and Devices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434499/
https://www.ncbi.nlm.nih.gov/pubmed/30918671
http://dx.doi.org/10.15420/aer.2018.71.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434499/
https://www.ncbi.nlm.nih.gov/pubmed/30918671
http://dx.doi.org/10.15420/aer.2018.71.2

Ejemplares similares